SHIRE PLC - Director/PDMR Share Dealings

Director/PDMR Share Dealings

December23, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that Ordinary Shares ("Shares") and American Depositary Shares ("ADSs") of the
Company, as set out below, have been acquired today for the Non-Executive
Directors, being the part of their total fees that are paid in shares for the
period of service from October 1 to December 31, 2014.

                         Type of Security(1)     Number of Shares/ADSs

Dominic Blakemore              Shares                           122

William Burns                  Shares                           119

Dr. Steven Gillis               ADSs                             37

Dr. David Ginsburg              ADSs                             41

David Kappler                  Shares                           123

Susan Kilsby (2)                ADSs                            150

Anne Minto                     Shares                           119

David Stout                     ADSs                             37

(1) One ADS is equal to three Shares.

(2) On October 23, 2014, Susan Kilsby's fee as Chairman of Shire plc was
increased to £450,000 per annum effective as of September 1, 2014. Twenty-five
per cent of this amount will continue to be paid in stock. The number of ADSs
acquired for Ms Kilsby, as referenced above, includes ADSs acquired in respect
of the pro rata amount of her fee increase for the month of September, 2014.

The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ
respectively at £46.4937 per Share and $217.4953 per ADS.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary


For further information please contact:

Investor Relations

Jeff Poulton                            [e-mail]   [phone]

Sarah Elton-Farr                        [e-mail] [phone]


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal, and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmics.

www.shire.com


Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release

www.shire.com